Nature Biotechnology
- 24, 1512 - 1514 (2006)
doi:10.1038/nbt1206-1512
Antibiotics—an investment worth making?Ralph E Christoffersen
Ralph Christoffersen is a General Partner at Morgenthaler Ventures, 4430 Arapahoe Avenue, Suite 220, Boulder, Colorado 80303, USA. Morgenthaler is an investor in Replidyne, Inc., and Christoffersen is a member of the Board of Directors of Replidyne. rchris@morgenthaler.com
Antibiotics markets are huge and the need for new classes of antibiotics is great, but the risks give investors pause.
|
